Key result
This review provides an overview of strategies to prevent and limit anthracycline-induced cardiotoxicity in childhood cancer survivors.
Why the study?
What are the possible strategies to prevent or limit anthracycline-induced cardiotoxicity in pediatric cancer patients?
What are the possible strategies to prevent or limit anthracycline-induced cardiotoxicity in pediatric cancer patients?
This review summarizes strategies for cardioprotection against anthracycline-induced cardiotoxicity in pediatric cancer patients.
Highlights strategies for anthracycline cardiotoxicity prevention in children; leaves open the need for prospective trials before adoption.
Notwithstanding the steady progress in survival rates of children and adolescents suffering from cancer, the benefits associated with chemotherapy do not come without risks involving multiple organs and systems, including the cardiovascular apparatus. Anthracyclines-often administered in combination with radiation therapy and/or surgery-are the most used chemotherapeutic compounds in order to treat tumours and blood malignancies even in paediatric age. Being an important side-effect of anthracyclines, carduitoxicity may limit their efficacy during the treatment and induce long-term sequelae, observed even many years after therapy completion. The purpose of this review was to perform an overview about all the possible strategies to prevent and/or limit the anthracyclines adverse side-effects for the cardiovascular system in childhood cancer survivors.
No takes yet. Share an insight, caveat, or question.
Bassareo et al. (2016) conducted a review in Anthracycline-induced cardiotoxicity in paediatric cancer. Cardioprotection strategies was evaluated. This review provides an overview of strategies to prevent and limit anthracycline-induced cardiotoxicity in childhood cancer survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: